• Hainan Cancer Prevention and Treatment Center
  • Tianjin Cancer Hospital Hainan Branch
  • Affiliated Cancer Hospital of Hainan Medical College


Tumor Chemotherapy Department

The department of Medical Oncology of Hainan Cancer Hospital is dedicated to the professional, standardized and individualized diagnosis and treatment of malignant tumors. Relying on the hospital’s  strong comprehensive strength, the department has significant advantages in cancer combined treatment, carries out treatment such as chemotherapy, molecular targeted therapy, immunotherapy in lung cancer, breast cancer, gastrointestinal tumors, head and neck cancer and lymphoma and so on. Organizes regular MDT discussions and provides patients with the best comprehensive and individualized therapies. The department develops health lectures on cancer prevention, propaganda education related to cancer diagnosis and treatment and follow-up regularly to supply high-quality services and whole-course care for cancer patients.


The department now has 22 medical staff, including 1 chief physician, 1 associate chief physician, 8 resident physicians and 12 nurses. Wei Zhixia, Director of the department is chief physician, associate professor, master tutor and graduate of Southeast University. She was selected by Jiangsu Education Department to the University of Colorado Cancer Center for further study and participated in some researches on clinical trials about cancer drugs in Harvard School of Public Health. Pursuing in the Oncology field more than 30 years, she is a senior clinical Oncologist. She is specialized in the diagnosis and combined treatment that is based on chemotherapy, molecular targeted precision therapy and immunotherapy of various malignant tumors.

Specialty therapy

At present, the department mainly carries out targeted therapy, immunotherapy, chemotherapy and so on for malignant tumors in various parts of the body. In particular, the department has rich clinical experience in the treatment of molecular targeted drugs, such as trastuzumab/pastuzumab for HER2-positive breast cancer patients, and cetuximab/bevacizumab for advanced colorectal cancer patients. Professor Wei Zhixia, as the chief expert of Boao Super Hospital, has carried out the clinical application of many international new drugs, and has taken the lead in the clinical use of the immunosuppressant PD-1 in melanoma, lung cancer, etc. As the International Clinical Application Center of new drugs, Boao Super Hospital will carry out more clinical application of new tumor drugs.

Copyright © 2019 Hainan Cancer Hospital All Rights Reserved.